ArticleEndocrine oncology (Bristol, England)2026
Patient-reported symptom and urgent healthcare use in neuroendocrine tumors.
Article in Endocrine oncology (Bristol, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with neuroendocrine tumors (NETs) have a high burden of symptoms persisting over years after diagnosis. Patient-reported outcome measures are routinely screened for in oncology practice but seldom used for interventions. Further information about how they are linked to outcomes could improve their use. We examined the association between patient-reported symptoms and urgent healthcare use after NET diagnosis. Patients and methods: We conducted a population-level retrospective cohort study of adults diagnosed with NETs over 2010-2019. The exposure was Edmonton Symptom Assessment System (ESAS) scores within 2 years of diagnosis. The outcome was urgent healthcare utilization (emergency department visits and/or unplanned hospital admission) in 14 days after ESAS assessment. Logistic regression models examined the association between ESAS scores and the outcome. Results: A total of 4,278 patients completed 19,612 ESAS assessments. Each 1-point increment in drowsiness (OR: 1.03, 95% CI: 1.00-1.07), lack of appetite (OR: 1.09, 95% CI: 1.06-1.12), pain (OR: 1.08, 95% CI: 1.05-1.11), and poor well-being (OR: 1.05, 95% CI: 1.01-1.09) scores was associated with higher urgent healthcare use, after adjustment. We computed a global ESAS score using the highest individual symptom score (high-ESAS) for each assessment. Each 1-point increase in high-ESAS was associated with a 21% increase in the odds of urgent healthcare use (OR: 1.21, 95% CI: 1.18-1.24). Conclusion: ESAS scores are associated with subsequent short-term urgent healthcare use after NET diagnosis. This indicates a potential gap in managing outpatient patient-reported symptoms. Routine monitoring of ESAS scores could be leveraged to identify patients at high risk of urgent healthcare use in need for better symptom management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.